VIVUS, Inc. (Nasdaq:VVUS)
November 14th, 2018
VIVUS, Inc. finished Tuesday’s trading session down 2.92%, a $0.10 decrease to close on $3.33. As well as the drop in value, VIVUS, Inc. hit a new 52 week low of $3.27. Two technical ‘scores’ for stocks to be wary of are the Altman Z1 and the Piotroski2 scores. VVUS scored quite low for both, which could be indicators of trouble down the road (the Altman Z-Score is -3.79, and the Piotroski Score is 2).
VVUS was outperformed by the rest of the Healthcare sector which went down just 0.68%.
The market sectors were mixed Wednesday with a majority of the sectors trending down. Financials saw the biggest increase of the day (0.59%), while Energy saw the biggest drop (2.39%). Healthcare has seen the biggest year-to-date gain at 10%. The biggest loss this year has been the Communication Services sector declining 12%.
Financials saw the biggest turnaround from its 5-day performance of -0.74%, as it went up 0.59%. Healthcare and Consumer Staples experienced turn arounds from their five day positive performance, Healthcare with a drop of 0.68%.
- Financials went up with a 0.59% change.
- Industrials went up with a 0.45% change.
- Utilities went up with a 0.35% change.
- Real Estate went up with a 0.14% change.
- Information Technology went up with a 0.09% change.
- Consumer Discretionary went down with a -0.03% change.
- Communication Services went down with a -0.27% change.
- Materials went down with a -0.29% change.
- Consumer Staples went down with a -0.37% change.
- Healthcare went down with a -0.68% change.
- Energy went down with a -2.39% change.
Vivus is based in Mountain View, United States of America.
VIVUS, Inc. Info
VIVUS, Inc., a biopharmaceutical company, develops and commercializes novel therapeutic products to address unmet medical needs in human health in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or obese patients, or 27 or greater, or overweight patients in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It is also involved in developing Qsymia, which has been completed Phase II studies for the treatment of various diseases, including obstructive sleep apnea and diabetes, nonalcoholic steatohepatitis and fatty liver disease, hyperlipidemia, and hypertension, as well as Tacrolimus that has been completed Phase IIa studies for the treatment of pulmonary arterial hypertension. The company has development, license and clinical trial, and commercial supply agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. It also has license and commercialization agreements with Berlin Chemie AG to commercialize and promote STENDRA. VIVUS, Inc. was founded in 1991 and is headquartered in Campbell, California.
All amounts in USD unless otherwise indicated
(1) The Altman Z-Score calculation was first published in 1968 by Edward I. Altman, and is used for predicting the probability that a firm will go into bankruptcy within two years. An Altman Z-Score below 1.8 (Remember that VIVUS, Inc.’s score is -3.79) is the trigger to be alert for this situation. Some analysts believe this score is less relevant for some companies, in particular companies operating to accumulate users that may run at huge losses to scale up.
(2) The Piotrosky score is used to determine the best value stocks with nine being the best and zero being the worst. It is based on specific aspects of the company’s financial statements, such as positive net income, operating cash flow and asset turnover ratio. A score 0 0 is the worst (VIVUS, Inc.’s score is 2), and 9 is the best.
Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.